1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Apokyn (Parkinson’s Disease) - Forecast and Market Analysis to 2022

Apokyn (Parkinson’s Disease) - Forecast and Market Analysis to 2022

Summary

Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

The anti-Parkinsonian effect of apomorphine was first discovered in 1951. Its use was limited due to severe side effects such as nausea, vomiting, postural hypotension, and sedation, which was partially alleviated with use of the dopamine antagonist domperidone (Pietz et al., 1998). In addition, oral use is associated with nephrotoxicity (Ostergaard et al., 1995). It was developed as a self-injectable pen or continuous infusion by Britannia Pharmaceuticals and Laboratoire Aguettant under the name Apo-go, later renamed Apokyn in the US and Japan.

Scope

- Overview of Parkinson’s disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Apokyn including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Apokyn for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Parkinson’s disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Apokyn performance
- Obtain sales forecast for Apokyn from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Table Of Contents

Apokyn (Parkinson’s Disease) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 15
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18
4 Disease Management 20
4.1 Overview 20
4.1.1 Diagnosis - The UK Brain Bank Criteria 20
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.2 Treatment Synopsis 24
4.2.1 Dopaminergic Therapy Classes 24
4.2.2 Treatment of Parkinson's Disease by Stage 26
4.2.3 Other Treatment Options 29
4.3 Parkinson's Disease Assessment Scales 29
4.3.1 Unified Parkinson's Disease Rating Scale (UPDRS) 30
4.3.2 Hoehn and Yahr Clinical Staging 32
4.3.3 Other Clinical Assessments 33
5 Competitive Assessment 34
5.1 Overview 34
5.2 Strategic Competitor Assessment 36
5.3 Dopamine Agonists 38
6 Apokyn (apomorphine) 39
6.1 Overview 39
6.2 Efficacy 41
6.3 Safety 41
6.4 SWOT Analysis 42
6.5 Forecast 42
7 Appendix 44
7.1 Bibliography 44
7.2 Abbreviations 48
7.3 Methodology 51
7.4 Forecasting Methodology 51
7.4.1 Diagnosed Parkinson's Disease Patients 51
7.4.2 Percent Drug-Treated Patients 52
7.4.3 General Pricing Assumptions 52
7.4.4 Compliance Assumptions 53
7.4.5 Individual Drug Assumptions 54
7.4.6 Generic Erosion 54
7.5 Physicians and Specialists Included in this Study 55
7.6 About the Authors 57
7.6.1 Author 57
7.6.2 Global Head of Healthcare 58
7.7 About GlobalData 59
7.8 Disclaimer 59

1.1 List of Tables

Table 1: Symptoms of Parkinson's Disease 19
Table 2: UK Brain Bank Diagnostic Criteria 21
Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease 22
Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014 23
Table 5: Dopaminergic Therapy in Parkinson's Disease 26
Table 6: UPDRS Clinical Assessment of Disease Severity 31
Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials 33
Table 8: Treatment of Motor Symptoms in Parkinson's Disease 35
Table 9: Leading Treatments for Parkinson's Disease, 2014 37
Table 10: Product Profile - Apokyn 40
Table 11: Apokyn SWOT Analysis, 2014 42
Table 12: Global Sales Forecasts ($m) for Apokyn Continuous Infusion, 2012-2022 43
Table 13: Global Sales Forecasts ($m) for Apokyn Pen, 2012-2022 43

1.2 List of Figures

Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes 25
Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Schizophrenia - US Drug Forecast and Market Analysis to 2025

Schizophrenia - US Drug Forecast and Market Analysis to 2025

  • $ 4995
  • Industry report
  • November 2016
  • by Global Data

Schizophrenia - US Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.